Streetbeat News

Stock Prices

YTRA

Yatra Online shares are trading lower after the company reported worse-than-expected Q1 sales results.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:06 pm

QLI

Qilian International Holding Group Ltd. (NASDAQ:QLI) announced that its Class A ordinary shares will begin trading under the new ticker symbol 'BGM' on the Nasdaq Capital Market effective August 11, 2024. The new ticker symbol will replace the current 'QLI'.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:06 pm

APLM

Apollomics announced preliminary data from its Phase 2 SPARTA trial, showing a 43% objective response rate for Vebreltinib in patients with non-CNS MET fusion solid tumors.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:06 pm

CADL

Candel Therapeutics (NASDAQ:CADL) reported a significant increase in quarterly losses, with Q2 EPS at $(0.74), down from $(0.33) YoY, marking a 124.24% decrease.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:05 pm

GNLN

Greenlane Holdings CEO Barbara Sher has acquired 12,500 common shares on the open market at an average price of $2.66 per share between August 5-9, indicating confidence in the company's growth prospects.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:05 pm

ALUR

Allurion Technologies has revised its full-year 2024 revenue guidance to $40 million-$45 million, down from the previous $60 million-$65 million, and below the $55 million estimate. The company expects a 10%-15% growth in procedure volume.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:04 pm

NRBO

NeuroBo Pharmaceuticals has completed enrollment for the Single Ascending Dose (SAD) part of its Phase 1 trial for the obesity treatment DA-1726. No significant issues were encountered, allowing for an accelerated start to the Multiple Ascending Dose (MAD) part. Top-line data for SAD is expected in Q3 2024, and MAD data in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:04 pm

GALT

Galectin Therapeutics (NASDAQ:GALT) reported a Q2 EPS of $(0.20), missing the analyst consensus estimate of $(0.16) by 25%. This represents a 33.33% increase in losses compared to $(0.15) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:03 pm

URGN

UroGen Pharma reported its Q2 2024 financial results, with a GAAP EPS of $(0.91), missing the estimate of $(0.86). Sales were $21.848 million, also missing the estimate of $23.963 million.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:03 pm

IINN

Inspira Technologies announced a successful evaluation of its proprietary product integrated with the INSPIRA ART100 system, which exceeded 100% of the standard gas transfer value at maximum flow.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:03 pm